GSK's Jemperli hits goal in phase 2 trial for rectal cancer
Seeking Alpha ·
GSK ( GSK ) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer given Jemperli (dostarlimab) showed a sustained complete clinical response rate at one year. Enrolled patients had stage II/III mismatch
AI 시장 분석
GSK has achieved its target in the phase 2 clinical trial of rectal cancer treatment Jemperli. In the clinical trial, 71 out of 100 rectal cancer patients showed sustained complete clinical response for 1 year.
상승 영향
- Biotech — GSK's Jemperli's success in rectal cancer treatment is an important indication of the drug's efficacy.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
482 participants